How to Switch CDMOs Without Losing Control of Your Manufacturing Program

Sometimes the CDMO that made sense at the beginning of a program stops making sense later.

The program may have outgrown the facility.

Capacity may be too limited.

Timelines may no longer work.

Costs may have changed.

The relationship may be difficult to manage.

Or the product may simply need capabilities the current manufacturing partner does not have.

Changing CDMOs can be necessary.

It can also be disruptive if the sponsor treats it as a simple vendor replacement.

The process, methods, materials, knowledge, documentation, and manufacturing schedule all need a transition plan.

The reason matters because it affects what you look for next.

Common drivers might include:

• capacity
• scale
• technical capability
• service quality
• timeline
• geographic strategy
• commercial considerations
• lifecycle needs

If the sponsor does not clearly understand what failed in the existing arrangement, it can easily recreate the same problem with the next partner.

Before starting the search, define what the replacement CDMO needs to do differently.

A rushed CDMO transition gives the sponsor fewer options.

If warning signs appear early, it may be useful to begin understanding the alternative market before an emergency develops.

That does not mean immediately abandoning the existing manufacturer.

It means knowing:

• which alternatives exist
• how long transfer may take
• what manufacturing slots are available
• what data and materials would need to move

Optionality is easier to build before the program is in crisis.

Changing manufacturers can involve contractual obligations.

Sponsors may need to understand issues related to:

• termination
• outstanding commitments
• material ownership
• documentation
• intellectual property
• data access
• reserved manufacturing slots

These issues should be reviewed with qualified legal and commercial advisors.

The manufacturing transition plan should reflect what the existing agreements actually allow and require.

Before approaching replacement manufacturers, understand what needs to move.

That may include:

• process descriptions
• batch records
• development reports
• analytical methods
• specifications
• raw-material information
• stability data
• validation information
• reference standards
• manufacturing materials
• cell banks or other biological materials where relevant

The exact package depends on the product.

The goal is to understand what the next CDMO will need in order to receive the process.

Manufacturing processes often contain tacit knowledge.

The current technical team may know:

• which steps are difficult
• where yield is lost
• which raw materials cause problems
• which parameters are particularly sensitive
• which deviations have occurred
• how previous scale-up problems were solved

That knowledge can disappear during a supplier transition unless it is deliberately captured.

The transfer should include people, not just files.

The new CDMO search should reflect what the sponsor has learned.

A process that was early-stage during the first sourcing exercise may now be:

• more mature
• larger scale
• closer to commercial
• better characterized
• more technically demanding

Do not simply rerun the original CDMO selection criteria.

Define the requirements as they exist today.

Sometimes the goal is to reproduce the current manufacturing setup as closely as possible.

In other cases, switching creates an opportunity to change the strategy.

The sponsor might move:

• from a small CDMO to a larger-scale manufacturer
• from several suppliers to an integrated CDMO
• from an integrated provider to specialists
• from one geography to another

A transition can solve more than one manufacturing problem if the new model is designed deliberately.

Equipment differences can materially affect technology transfer.

Ask replacement CDMOs to review the process before assuming it will transfer directly.

Potential differences may involve:

• vessel size
• mixing
• filtration
• chromatography
• filling systems
• control systems
• analytical instrumentation

A manufacturer with the right service category may still require substantial process adaptation.

Changing manufacturing sites can affect the process or product.

Depending on the program, the sponsor may need technical, analytical, quality, or regulatory work to support the transition.

The appropriate strategy is product-specific and should be developed with qualified CMC and regulatory teams.

Analytical methods can become one of the slower parts of the transition.

The replacement CDMO may need to:

• receive methods
• train personnel
• obtain reagents
• acquire reference standards
• demonstrate method performance
• coordinate outsourced testing

Analytical transfer should therefore be included in the transition timeline from the beginning.

The sponsor should understand what physical materials need to move between organizations.

Depending on the program, that could include:

• raw materials
• starting materials
• intermediates
• drug substance
• reference standards
• cell banks
• plasmids
• samples

Storage, shipping, release status, ownership, and documentation may all matter.

Where practical, the sponsor may benefit from maintaining some overlap between the outgoing and incoming manufacturers.

That can reduce the risk of creating a complete supply gap.

The appropriate overlap depends on:

• inventory
• contracts
• product stability
• development stage
• cost
• manufacturing timeline

Not every company can support parallel operations, but the risk should at least be evaluated.

A switch should not be planned around the date the sponsor wants to sign with a new CDMO.

Start with the date the program needs usable material.

Then work backward through:

manufacturing → release → engineering work → analytical transfer → process transfer → contracting → supplier selection

That often reveals that the replacement process needs to begin earlier than expected.

A replacement manufacturer should not receive less diligence simply because the sponsor is under time pressure.

Technical fit, facility fit, quality qualification, regulatory context, commercial terms, and capacity still matter.

The urgency of leaving the old CDMO should not become the reason for choosing the wrong new one.

A difficult supplier relationship can become emotional.

That rarely improves the transition.

The outgoing manufacturer may still hold:

• important process knowledge
• materials
• data
• documentation
• samples

A professional transition can make it easier to obtain the information the next CDMO needs.

Contractual and legal issues should be handled through the appropriate channels.

Pharma Connect Navigator can help sponsors search the manufacturing market using the requirements the program has today.

That may be particularly useful during a CDMO transition because the sponsor often understands the process and its manufacturing needs better than it did during the original search.

PCN helps teams identify potentially relevant companies and facilities, compare project fit, investigate available capabilities, equipment, scale, and regulatory context, and begin structured conversations with alternative manufacturers.

PCN does not manage the technology transfer or determine the regulatory strategy for switching manufacturers.

It can help the sponsor identify replacement options before those deeper transition activities begin.